Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients

• Published in: Clinical therapeutics Vol. 42; no. 5; pp. 818 - 829
• Main Authors: Li, Li, Wu, Hailan, Chen, Yuancheng, Yuan, Hong, Wu, Junzhen, Wu, Xiaojie, Zhang, Yingyuan, Cao, Guoying, Guo, Beining, Wu, Jufang, Zhao, Ming, Zhang, Jing
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2020; Elsevier Limited
• Subjects: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - pharmacokinetics; Bacteria; Body Weight; Clinical trials; Creatinine; Dosage; Drug dosages; Drug resistance; FDA approval; Female; Food; Food intake; Food-Drug Interactions; healthy subjects; Healthy Volunteers; Humans; Internal Medicine; Male; Medical Education; Methicillin; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Minimum inhibitory concentration; Models, Biological; Monte Carlo Method; Monte Carlo simulation; MRX-I; Multidrug resistant organisms; Nosocomial infections; Oral administration; Oxazolidinones - administration & dosage; Oxazolidinones - pharmacokinetics; Pathogens; patients; pharmacodynamic pharmacokinetics; Pharmacodynamics; Pharmacokinetics; Plasma; Population; Population studies; Population-based studies; Pyridones - administration & dosage; Pyridones - pharmacokinetics; Skin; Skin Diseases - drug therapy; Skin Diseases - metabolism; Staphylococcal Infections - drug therapy; Staphylococcal Infections - metabolism; Staphylococcus aureus; Staphylococcus infections; Streptococcus infections; Young Adult; United States > US; Massachusetts; pharmacodynamic pharmacokinetics; PK; PD; MRX-I; healthy subjects; patients

Contezolid (MRX-I) is a novel oxazolidinone with potent in vitro activity against gram-positive pathogens. The aim of this study was to establish the dose-pharmacokinetic (PK) exposure-pharmacodynamic (PD)–response relationship and to quantitatively evaluate the variability of MRX-I after continuous...